DIAGNOSTIC ULTRASOUND IMAGING CONTRAST AGENTS

Brand Owner (click to sort) Address Description
ECHOBRITE Molecular Biosystems, Inc. Suite A 11180 Roselle St. San Diego CA 92121 diagnostic ultrasound imaging contrast agents;ECHO BRITE; ECHO BRIGHT;
GASTROBRITE Molecular Biosystems, Inc. Suite A 11180 Roselle St. San Diego CA 92121 diagnostic ultrasound imaging contrast agents;GASTRO BRITE; GASTRO BRIGHT;
MICRONEX Molecular Biosystems, Inc. Suite A 11180 Roselle St. San Diego CA 92121 diagnostic ultrasound imaging contrast agents;MICRO-NEX;
MICRONEX Molecular Biosystems, Inc. Suite A 11180 Roselle St. San Diego CA 92121 diagnostic ultrasound imaging contrast agents;
MYOBRITE Molecular Biosystems, Inc. Suite A 11180 Roselle St. San Diego CA 92121 diagnostic ultrasound imaging contrast agents;
ORALEX Molecular Biosystems, Inc. Suite A 11180 Roselle St. San Diego CA 92121 diagnostic ultrasound imaging contrast agents for clinical medical use;
SONOBRITE Molecular Biosystems, Inc. Suite A 11180 Roselle St. San Diego CA 92121 diagnostic ultrasound imaging contrast agents;SONO-BRITE; SONO-BRIGHT;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention relates to a contrast-enhanced diagnostic imaging method for monitoring the efficacy of interventional therapies. The contrast agents useful in this method comprise an image-enhancing moiety (IEM) and a state-dependent tissue binding moiety (SDTBM). These contrast agents exhibit state-dependent binding to one or more components of a targeted tissue or tissue component and provide a detectable change in the signal characteristics of the agent once bound to the targeted tissue. As a result, these agents exhibit a binding affinity for, and thus image contrast of, the targeted tissue which changes as the tissue-state changes during therapy.